EXAS Exact Sciences Corp
Price (delayed)
$43.16
Market cap
$8.02B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.59
Enterprise value
$10.17B
Exact Sciences Corp. is a molecular diagnostics company with an initial focus on the early detection and prevention of colorectal cancer. Exact Sciences Corp. launched Cologuard in 2014, the first
Highlights
EXAS's revenue is up by 10% year-on-year and by 2.5% since the previous quarter
EXAS's gross profit is up by 9% year-on-year
The company's equity fell by 25% QoQ and by 24% YoY
The company's debt rose by 8% YoY
Key stats
What are the main financial stats of EXAS
Market
Valuations
Earnings
Shares outstanding
185.76M
Market cap
$8.02B
Enterprise value
$10.17B
Price to earnings (P/E)
N/A
Price to book (P/B)
3.33
Price to sales (P/S)
2.88
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.69
Revenue
$2.76B
Gross profit
$1.92B
Operating income
-$1.05B
Net income
-$1.03B
EBIT
-$1.01B
EBITDA
-$767.36M
Free cash flow
$74.55M
Per share
Balance sheet
Liquidity
EPS
-$5.59
EPS diluted
-$5.59
Free cash flow per share
$0.4
Book value per share
$12.98
Revenue per share
$14.98
TBVPS
$13.85
Total assets
$5.93B
Total liabilities
$3.53B
Debt
$2.75B
Equity
$2.4B
Working capital
$839.24M
Debt to equity
1.15
Current ratio
2.15
Quick ratio
1.76
Net debt/EBITDA
-2.81
Margins
Efficiency
Dividend
EBITDA margin
-27.8%
Gross margin
69.5%
Net margin
-37.3%
Operating margin
-38%
Return on assets
-16%
Return on equity
-34.5%
Return on invested capital
-25.8%
Return on capital employed
-19.4%
Return on sales
-36.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
EXAS stock price
How has the Exact Sciences stock price performed over time
Intraday
-6.88%
1 week
-7.46%
1 month
-14.69%
1 year
-29.34%
YTD
-23.19%
QTD
-23.19%
Financial performance
How have Exact Sciences's revenue and profit performed over time
Revenue
$2.76B
Gross profit
$1.92B
Operating income
-$1.05B
Net income
-$1.03B
Gross margin
69.5%
Net margin
-37.3%
EXAS's revenue is up by 10% year-on-year and by 2.5% since the previous quarter
EXAS's gross profit is up by 9% year-on-year
Growth
What is Exact Sciences's growth rate over time
Valuation
What is Exact Sciences stock price valuation
P/E
N/A
P/B
3.33
P/S
2.88
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.69
The company's equity fell by 25% QoQ and by 24% YoY
The stock's price to book (P/B) is 19% less than its 5-year quarterly average of 4.4 and 3.5% less than its last 4 quarters average of 3.7
EXAS's price to sales (P/S) is 58% less than its 5-year quarterly average of 7.3 and 25% less than its last 4 quarters average of 4.1
EXAS's revenue is up by 10% year-on-year and by 2.5% since the previous quarter
Efficiency
How efficient is Exact Sciences business performance
Dividends
What is EXAS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for EXAS.
Financial health
How did Exact Sciences financials performed over time
The total assets is 68% more than the total liabilities
The total assets has contracted by 12% from the previous quarter and by 8% YoY
The company's quick ratio fell by 8% YoY
The company's debt is 15% higher than its equity
EXAS's debt to equity is up by 42% year-on-year and by 34% since the previous quarter
The company's equity fell by 25% QoQ and by 24% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.